ロード中...
Targeted treatments in advanced renal cell carcinoma: focus on axitinib
Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3977458/ https://ncbi.nlm.nih.gov/pubmed/24715765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S37098 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|